Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

After Pfizer (PFE) posted a third quarter earnings beat and raised its full-year guidance, CEO Albert Bourla joins Market ...

Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We remain focused on advancing our late-stage oncology product candidates towards potential registration. We believe our pipeline and ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.

Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Fifteen months on from completion of the BioNTech acquisition, co-founder and CEO Karim Beguir told TechCrunch in an interview that Instadeep has made significant progress on that front, even as the ...

However, he disagrees with "a lot" of other points, like spending and acquisitions, and calls the Pfizer-BioNTech (BNTX) deal "transformational." He notes that Starboard Value CEO Jeff Smith has ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

Fifteen months on from completion of the BioNTech acquisition, co-founder and CEO Karim Beguir told TechCrunch in an interview that InstaDeep has made significant progress on that front ...